PMN

Business Context and Reporting Period

Company: ProMIS Neurosciences Inc. (PMN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: ProMIS is a clinical-stage biopharmaceutical company developing antibody therapies for neurodegenerative diseases, specifically Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS). The company has no product revenue and relies on external financing.

Key Financial Metrics

Note: Working capital is calculated as Total Current Assets ($9,509,496) minus Total Current Liabilities ($9,824,087).

Material Changes vs. Prior Period

• Significant Increase in R&D Spend: R&D expenses surged by $10.5 million (284%) year-over-year, primarily driven by the commencement of the Phase 1b "PRECISE-AD" clinical trial for lead candidate PMN310. Direct costs for PMN310 increased by $10.2 million.
• Net Loss Expansion: Net loss for the six-month period more than doubled to $17.5 million from $6.3 million in the prior year period.
• Liquidity Deterioration: Cash and short-term investments decreased by approximately $8.8 million during the period. Current liabilities increased significantly to $9.8 million (from $2.2 million), largely due to accrued R&D liabilities ($6.6 million) and accounts payable.
• Share-Based Compensation: Total share-based compensation expense increased to $457,310 from $81,583 in the prior year period.

Outlook, Risks, and Subsequent Events

Going Concern Warning

Management has raised substantial doubt about the Company's ability to continue as a going concern for the next 12 months. Despite cash on hand of $4.5 million as of June 30, 2025, the Company expects to incur net losses for the foreseeable future and requires additional funding to sustain operations and clinical trials.

Subsequent Financing (July 2025)

Following the reporting period, the Company secured approximately $21.6 million in gross proceeds through:

• Discounted exercise of warrants from the July 2024 PIPE offering (~$15.9 million).
• Registered Direct Offering (~$0.8 million).
• Private Placement (PIPE) offerings (~$5.4 million).

Clinical Progress

• PMN310 (Alzheimer's): Received FDA Fast Track Designation (July 2025). Phase 1b trial enrollment is >50% complete with no observed cases of Amyloid-Related Imaging Abnormalities (ARIA).
• PMN267 (ALS) & PMN442 (MSA): Candidates are humanized and ready for IND-enabling studies, subject to funding availability.

Internal Control Material Weakness

The Company identified a material weakness in internal controls over financial reporting related to insufficient review controls over fair value calculations of financial instruments (specifically the July 2024 PIPE Warrant Liability). Management concluded that disclosure controls and procedures were not effective as of June 30, 2025.

Investor Verification Checklist

• Runway Analysis: Verify if the $21.6 million raised in July 2025 is sufficient to fund the Phase 1b trial and operations for the next 12 months, given the high burn rate.
• Dilution Impact: Assess the dilution from the recent warrant exercises and PIPE offerings, noting the significant number of warrants outstanding (57.1 million).
• Internal Controls: Monitor the remediation plan for the identified material weakness in fair value accounting to ensure future financial reporting reliability.
• Clinical Milestones: Track the timeline for the 6-month interim data release for PMN310 (expected Q2 2026) and the potential impact on Tranche A and B warrant exercises.
• Liability Accruals: Review the composition of the $7.0 million in accrued liabilities, specifically the $6.6 million related to R&D, to understand payment obligations.